Imperial College London
Alternate

ProfessorJaneMitchell

Faculty of Medicine, National Heart & Lung Institute

Professor of Pharmacology in Critical Care Medicine
 
 
 
//

Contact

 

+44 (0)20 7351 8137j.a.mitchell

 
 
//

Assistant

 

Ms Lisa Quinn +44 (0)20 7594 1345

 
//

Location

 

Sir Alexander Fleming BuildingSouth Kensington Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Mitchell:2019:10.1111/bph.14167,
author = {Mitchell, J and Kirkby, NS},
doi = {10.1111/bph.14167},
journal = {British Journal of Pharmacology},
pages = {1038--1050},
title = {Eicosanoids, prostacyclin and cyclooxygenase in the cardiovascular system},
url = {http://dx.doi.org/10.1111/bph.14167},
volume = {176},
year = {2019}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Eicosanoids represent a diverse family of lipid mediators with fundamental roles in controlling  physiology  and  disease. Within  the  eicosanoid  super  family  are prostanoids,  which  are  specifically  derived  from  arachidonic  acid  by  the  enzyme cyclooxygenase(COX). COX has  two  isoforms; COX-1  and COX-2. COX-2  is  the therapeutic target for the nonsteroidal anti-inflammatory drug (NSAID) class of pain medications. Of the prostanoids,prostacyclin, first discovered by Sir Professor John Vane in 1976,remains amongst the best studied and retains an impressive pedigree as onethe bodies fundamental cardiovascular protective pathways. Since this time, we have learnt much about how eicosanoids, COXenzymes and prostacyclin function in  the  cardiovascular  system  which  has  allowed  us  to,  for  example,  harness  the power  of  prostacyclin  as  therapy  to  treat  pulmonary arterial hypertension  and peripheral vascular disease. However, there remain many unanswered questions in our  basic  understanding  of  the  pathways  and  how  they  can  be  usedto  improve human health. Perhaps the most importantand controversial outstanding question in  the  field  remains;‘how do NSAIDsproduce their much publicized cardiovascular side  effects?’This  review summarises  the  history,  biology  and  cardiovascular function  of  key  eicosanoids  with  particular  focus  on  prostacyclin  and  other COXproducts and discusses how our knowledge of these pathways can applied in future drug discovery and be used to explain the cardiovascular side effects of NSAIDs.
AU  - Mitchell,J
AU  - Kirkby,NS
DO  - 10.1111/bph.14167
EP  - 1050
PY  - 2019///
SN  - 1476-5381
SP  - 1038
TI  - Eicosanoids, prostacyclin and cyclooxygenase in the cardiovascular system
T2  - British Journal of Pharmacology
UR  - http://dx.doi.org/10.1111/bph.14167
UR  - http://hdl.handle.net/10044/1/57233
VL  - 176
ER  -
Download